Arm Jonathan P
Department of Medicine, Harvard Medical School, Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA.
Allergy Asthma Proc. 2004 Jan-Feb;25(1):37-42.
Since the elucidation of the structure of the cysteinyl leukotrienes (LTs) > 20 years ago, considerable progress has been made in our understanding of the role of these molecules in health and disease, particularly regarding bronchial asthma. This study will review the biochemistry of the 5-lipoxygenase pathway for LT generation. It will discuss the early evidence that LTs, the cysteinyl LTs in particular, have the biological properties expected for molecules that participate in the pathogenesis of bronchial asthma and the evidence for their formation in the airways of asthmatic individuals. It will briefly review tile evidence that LT-modifying drugs are effective in the management of bronchial asthma and will discuss novel developments in our understanding of the proinflammatory properties of the LTs including their role as autocrine mediators of leukocyte responses. The pharmacogenomics of 5-lipoxgenase and LTC4 synthase in bronchial asthma will be discussed.
自从20多年前半胱氨酰白三烯（LTs）的结构被阐明以来，我们对这些分子在健康和疾病中的作用，尤其是在支气管哮喘方面的作用的理解取得了相当大的进展。本研究将综述LT生成的5-脂氧合酶途径的生物化学。它将讨论早期证据，即LTs，特别是半胱氨酰LTs，具有参与支气管哮喘发病机制的分子所预期的生物学特性，以及它们在哮喘患者气道中形成的证据。它将简要综述LT修饰药物在支气管哮喘治疗中有效的证据，并将讨论我们对LTs促炎特性理解的新进展，包括它们作为白细胞反应自分泌介质的作用。还将讨论支气管哮喘中5-脂氧合酶和白三烯C4合酶的药物基因组学。
